Memantine Grindeks

Memantine, the active ingredient in Memantine Grindeks, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is used to treat cognitive decline associated with Alzheimer’s disease in adult patients.

GNH USA supplies Memantine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is an NMDA receptor antagonist indicated for the treatment of Alzheimer’s disease and related cognitive disorders. - Mild to moderate Alzheimer’s disease: improves cognition and daily functioning in patients with early‑stage disease. - Moderate to severe Alzheimer’s disease: helps maintain functional abilities as disease progresses. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression associated with the condition.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Headache: mild to moderate head pain. - Constipation: reduced bowel movements. - Fatigue: feeling unusually tired. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Seizures: rare occurrence of convulsive episodes. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Hallucinations or psychosis: rare visual or auditory disturbances. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals. - Liver function abnormalities: elevated liver enzymes detected in lab tests.

Before initiating therapy, consider patient‑specific factors and safety measures. - Renal impairment: adjust dose or monitor renal function closely. - Hepatic disease: use with caution and monitor liver enzymes. - History of seizures: evaluate risk versus benefit. - Concomitant use of other NMDA antagonists: avoid additive neuro‑psychiatric effects. - Pregnancy and breastfeeding: only use if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Memantine may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neuropsychiatric side effects. - Ketamine: additive CNS depression and dissociative effects. - High‑dose anticholinergics: may exacerbate cognitive impairment.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may reduce memantine absorption; monitor therapeutic response. - Certain antihypertensives: potential additive hypotensive effect. - Drugs affecting renal clearance (e.g., cimetidine): may increase memantine plasma levels.